/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CENTESSA PHARMACEUTICALS-ADR

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$29 0.0196(1.96%) CNTA at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 28.67
Highest Today 29.51
Today’s Open 28.71
Prev. Close 28.51
52 Week High 29.99
52 Week Low 9.60
Day’s Range: Low 28.67 High 29.51
52-Week Range: Low 9.60 High 29.99
1 day return -
1 Week return -
1 month return +22.38
3 month return +84.04
6 month return +131.27
1 year return +69.15
3 year return +628.32
5 year return -
10 year return -

Institutional Holdings

Medicxi Ventures Management (Jersey) Ltd 14.89

Index Venture Life Associates VI Ltd 7.43

General Atlantic Llc 7.22

Adage Capital Partners Gp LLC 6.27

HHG PLC 4.87

T. Rowe Price Associates, Inc. 4.41

venBio Select Advisor LLC 3.73

Farallon Capital Management, L.L.C. 3.38

First Light Asset Management, LLC 3.20

FMR Inc 2.85

Siren, L.L.C. 2.58

COMMODORE CAPITAL LP 2.46

T. Rowe Price Health Sciences 2.22

Fidelity Select Biotechnology 2.17

TCG Crossover Management, LLC 2.16

Point72 Asset Management, L.P. 1.93

Franklin Resources Inc 1.90

Cormorant Asset Management, LLC 1.56

Morgan Stanley - Brokerage Accounts 1.34

Millennium Management LLC 1.24

RTW INVESTMENTS, LLC 1.14

StemPoint Capital LP 0.94

Franklin Biotechnology Discv A(acc)USD 0.88

Polar Capital Biotech S Inc 0.75

Janus Henderson Triton D 0.71

Janus Henderson US SMID Cap Growth 0.71

Janus Henderson US SMID Cap Growth MA 0.71

American Century Small Cap Growth Inv 0.66

American Century U.S. Small Cap Growth 0.66

Fidelity VIP Mid Cap Initial 0.52

US Small-Cap Growth II Equity Comp 0.51

Franklin Biotechnology Discovery A 0.51

Franklin US Small Cap Growth Equity 0.50

Janus Henderson Hrzn Biotec E2 USD 0.46

Franklin Small Cap Growth Adv 0.46

T. Rowe Price New Horizons 0.43

T. Rowe Price Integrated US SmCapGrEq 0.39

T. Rowe Price Integrated US Sm Gr Eq 0.39

Janus Henderson US Small Cap Growth 0.37

Janus Henderson Venture D 0.37

Market Status

Strong Buy: 7

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4214.35 M

PB Ratio 14.2294

PE Ratio 0.0

Enterprise Value 4083.43 M

Total Assets 576.80 M

Volume 2015355

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:null 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-157421000 -157.4M, FY22:-216207000 -216.2M, FY21:-381071000 -381.1M, FY20:-11041000 -11.0M, FY19:-5284000 -5.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:15000000 15.0M, Q4/2024:null 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-228674 -0.2M, Q1/2025:15000000 15.0M, Q4/2024:null 0.0M, Q3/2024:-236264 -0.2M

Quarterly Net worth Q3/2025:-54891000 -54.9M, Q2/2025:-50343000 -50.3M, Q1/2025:-26135000 -26.1M, Q4/2024:-42566000 -42.6M, Q3/2024:-43816000 -43.8M

Fund house & investment objective

Company Information Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Organisation Biotechnology

Employees 114

Industry Biotechnology

CEO Dr. Saurabh Saha M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow